Henan Lingrui Pharmaceutical Co Ltd banner

Henan Lingrui Pharmaceutical Co Ltd
SSE:600285

Watchlist Manager
Henan Lingrui Pharmaceutical Co Ltd Logo
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Watchlist
Price: 22.36 CNY -0.89% Market Closed
Market Cap: ¥12.7B

EV/GP

4.1
Current
4%
More Expensive
vs 3-y average of 4

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
4.1
=
Enterprise Value
¥12B
/
Gross Profit
¥3B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
4.1
=
Enterprise Value
¥12B
/
Gross Profit
¥3B

Valuation Scenarios

Henan Lingrui Pharmaceutical Co Ltd is trading above its 3-year average

If EV/GP returns to its 3-Year Average (4), the stock would be worth ¥21.58 (3% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-26%
Maximum Upside
+228%
Average Upside
70%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 4.1 ¥22.36
0%
3-Year Average 4 ¥21.58
-3%
5-Year Average 3.1 ¥16.5
-26%
Industry Average 7.6 ¥40.78
+82%
Country Average 13.6 ¥73.29
+228%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
12.7B CNY 4.1 15.9
US
Eli Lilly and Co
NYSE:LLY
883B USD 17.5 44.2
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.8 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 6.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 7.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.9 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 5.3 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 4.2 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.3 16.6
P/E Multiple
Earnings Growth PEG
CN
Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Average P/E: 21.8
15.9
12%
1.3
US
Eli Lilly and Co
NYSE:LLY
44.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Lower than 85% of companies in China
Percentile
15th
Based on 6 967 companies
15th percentile
4.1
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Henan Lingrui Pharmaceutical Co Ltd
Glance View

Market Cap
12.7B CNY
Industry
Pharmaceuticals

Nestled in the heart of China's Henan province, Henan Lingrui Pharmaceutical Co Ltd has quietly crafted a legacy in the pharmaceutical sector, blending traditional Chinese medicine with modern medical practices. Founded in an environment rich in natural resources, the company takes pride in its extensive portfolio that includes a broad range of pharmaceutical products such as tablets, injections, ointments, and Chinese patent medicines. The company's approach is an intricate dance between ancient wisdom and contemporary science, where herbal remedies are often synthesized with cutting-edge pharmaceutical manufacturing processes. Priding itself on research and development, Lingrui regularly collaborates with esteemed medical institutions, ensuring that its offerings remain both innovative and deeply rooted in traditional therapeutic principles. The financial heartbeat of Henan Lingrui is sustained through a strategic balance of domestic sales and international exports, capitalizing on the rising global demand for natural and alternative medicines. As the company expands its footprint, it continues to harness its robust supply chain and distribution channels to seamlessly deliver its products to hospitals, pharmacies, and health institutions across various regions. Indeed, the harmonious blend of traditional and modern methodologies not only defines Lingrui's operations but also shapes its revenue streams. By adhering to stringent quality standards and fostering partnerships, Henan Lingrui Pharmaceutical not only thrives in its local market but also competes in diverse international arenas, leveraging its unique product offerings as a cornerstone for financial growth.

Intrinsic Value
25.11 CNY
Undervaluation 11%
Intrinsic Value
Price ¥22.36
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett